N
Nicole Gentile
Researcher at Mayo Clinic
Publications - 28
Citations - 483
Nicole Gentile is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Microscopic colitis & Medicine. The author has an hindex of 7, co-authored 21 publications receiving 392 citations. Previous affiliations of Nicole Gentile include University of Chicago & NorthShore University HealthSystem.
Papers
More filters
Journal ArticleDOI
Autoimmune Enteropathy: A Review and Update of Clinical Management
TL;DR: Much of what is known about AIE has been gathered from case reports and small case series; therefore, more research in this evolving field is needed.
Journal ArticleDOI
Oesophageal narrowing is common and frequently under‐appreciated at endoscopy in patients with oesophageal eosinophilia
Nicole Gentile,David A. Katzka,Karthik Ravi,Stephen W. Trenkner,Felicity Enders,Jill M. Killian,Lori A. Kryzer,Nicholas J. Talley,J. A. Alexander +8 more
TL;DR: Estimation of the prevalence of oesophageal narrowing and its clinical relevance in patients with oesphageal eosinophilia is probably underestimated by endoscopy.
Journal ArticleDOI
The epidemiology of microscopic colitis in olmsted county from 2002 to 2010: A population-based study
Nicole Gentile,Sahil Khanna,Edward V. Loftus,Thomas C. Smyrk,William J. Tremaine,W. Scott Harmsen,Alan R. Zinsmeister,Patricia P. Kammer,Darrell S. Pardi +8 more
TL;DR: The incidence of microscopic colitis in Olmsted County residents has stabilized and remains associated with female sex and increasing age and the overall prevalence remained stable over the study period.
Journal ArticleDOI
Outcomes of Patients With Microscopic Colitis Treated With Corticosteroids: A Population-Based Study
Nicole Gentile,Adil A. Abdalla,Sahil Khanna,Thomas C. Smyrk,William J. Tremaine,William A. Faubion,Patricia P. Kammer,William J. Sandborn,Edward V. Loftus,Darrell S. Pardi +9 more
TL;DR: Patients with MC often respond to corticosteroid therapy, but with a high relapse rate, and patients treated with budesonide had a higher response rate and a lower risk of recurrence than prednisone.
Journal ArticleDOI
Association Between Ipilimumab and Celiac Disease
TL;DR: A 62-year-old man with chemotherapy-naive, castration-resistant metastatic prostate cancer presented with refractory diarrhea despite prolonged high-dose corticosteroid treatment after receiving 3 doses of ipilimumab as part of a phase 3 clinical trial.